F001 Future of Dermatology: Dermatology Beyond 2040
DESCRIPTION
Are you an innovator? Visionary? Problem solver? Entrepreneur? If you have a solution that could change the practice of dermatology, or medicine in general, we would love to hear about it! In this session, we welcome game changers from academia, industry, private practice, the tech field- anyone who can envision a better way forward.
This year, the "Future of Dermatology Symposium" will focus on the dynamic intersection of biopharma and academia. This session will feature expert lectures and abstract presentations on the latest advancements in dermatological research and technology. Attendees will explore the potential of new therapies, discuss emerging trends, and gain insights into how collaboration between industry and academia is paving the way for the next generation of dermatological treatments.
Our panel of experts in therapeutics, cosmetics, molecular technologies, AI, telemedicine, and mobile and imaging technologies will review applications and select the most ground-breaking abstracts and pro
LEARNING OBJECTIVES
Explore Cutting-Edge Innovations: To highlight the latest advancements in dermatology, focusing on novel therapies and technologies emerging at the intersection of biopharma and academic research.
Foster Collaborative Dialogues: To facilitate discussions between biopharma professionals, academic researchers, and clinicians, encouraging collaboration to accelerate the development of groundbreaking dermatological treatments.
Showcase Promising Research and Clinical Applications: To present innovative research through abstract presentations that demonstrate how new findings are translating into practical solutions for dermatological care and patient outcomes.
DIRECTOR
Hensin Tsao, MD, PhD
CO-DIRECTORS
Lilit Garibyan, PhD, MD, FAAD
Harvard Medical School & Wellman Center/Mass General Hospital
Allan C. Halpern, MD, FAAD
Memorial Sloan Kettering Cancer Center
Bobby Y. Reddy, MD, FAAD
Yevgeniy Semenov, MD, MS, FAAD
Sandy Sharon Tsao, MD, FAAD
DISCLOSURES
Lilit Garibyan, PhD, MD, FAAD
Annecy Bio – Board of Directors(Stock); Brixton Biosciences – Consultant(Fees), Stockholder(Stock); Clarity Cosmetics, Inc. – Stockholder Private Company(No Compensation Received); EyeCool – Stockholder(Stock); Matilda Venture Studio – Board of Directors(Stock);
Allan C. Halpern, MD, FAAD
Canfield Scientific, Inc. – Consultant(Other Financial Benefit); SpotDoc – Founder(Other Financial Benefit);
Bobby Y. Reddy, MD, FAAD
Pi Health – Employee (w-2 relationship)(Salary);
Yevgeniy Semenov, MD, MS, FAAD
Alterome Therapeutics – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Bristol Myers Squibb – Consultant (1099 relationship)(Honoraria); Galderma – Advisory Board(Honoraria); Journal of the American Academy of Dermatology – Other(Salary); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Pyxis Oncology – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria);
Hensin Tsao, MD, PhD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria);
Sandy Sharon Tsao, MD, FAAD
Beiersdorf, Inc. – Consultant (1099 relationship)(Honoraria); Epiphany Dermatology – Advisory Board(Stock); WorldCare Clinical LLC – Consultant (1099 relationship)(Honoraria);